evipedia.ai
← Back

Niacin for Health & Longevity

Evidence Review created on 10/16/2026 using AI4L / Opus 5.5

Also known as: Nicotinic Acid, Vitamin B3, Vitamin PP, Pyridine-3-carboxylic Acid, Niaspan, Niacor, Slo-Niacin, Endur-acin

Motivation

Niacin (nicotinic acid, vitamin B3) is an essential B vitamin found in meat, fish, legumes and fortified grains. Everyday dietary amounts meet a basic nutritional need, while doses around a hundred times higher have been used as a prescription drug for blood fats. The body also turns it into a molecule every cell needs to produce energy and repair damage, which draws interest from people focused on healthy aging.

For decades niacin was one of the few available agents used against high cholesterol and other blood-fat disorders. It was tested in some of the earliest long-term heart trials, beginning in the 1960s, and later in large trials on top of cholesterol-lowering statin drugs. More recent laboratory and clinical work has examined its role in cellular energy and the possible effects of its breakdown products on blood vessels.

This review examines the evidence on niacin for heart and blood vessel health, metabolic health and healthy aging, together with its side effects, forms, doses, interactions and monitoring, for health-focused adults evaluating whether it has a place in a longevity strategy.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and overview articles that discuss niacin’s role in nutrition, cardiovascular and longevity practice.

Content from Rhonda Patrick was not included: her niacin-focused Q&A is members-only, and the free cholesterol-supplement clip mentions niacin in only two sentences.

Content from Andrew Huberman was not included: web and on-site searches found only brief timestamped mentions of vitamin B3 within broader episodes (eye health, appetite), mainly about nicotinamide and other NAD+ precursors, with no substantive discussion of nicotinic acid.

Grokipedia

Nicotinic acid

Encyclopedic entry covering niacin’s chemistry, dietary sources, pellagra (niacin-deficiency disease), lipid-modifying doses, the null statin add-on trials, and side effects including flushing and liver toxicity.

Examine

Niacin (Vitamin B3)

Graded evidence summary noting cholesterol improvements without reduced cardiovascular disease risk, plus dosing ranges, formulations and the caution that many “no-flush” products contain no nicotinic acid.

ConsumerLab

B Vitamin Supplements Review (B Complexes, B6, B12, Biotin, Folate, Niacin, Riboflavin & More)

Independent label-accuracy testing of B vitamin products, including niacin, with Top Picks and toxicity cautions; the summary is public, while full results require membership.

Systematic Reviews

This section lists systematic reviews and meta-analyses on niacin’s cardiovascular effects, lipoprotein changes and adverse effects.

Mechanism of Action

Niacin works through two separate routes:

  • Receptor route (drug doses): Nicotinic acid activates HCAR2 (hydroxycarboxylic acid receptor 2, also called GPR109A), a receptor on fat cells that slows release of free fatty acids into blood (Tunaru et al., 2003). The liver then makes less VLDL (very-low-density lipoprotein, the main triglyceride carrier) and LDL (low-density lipoprotein, the main cholesterol carrier linked to artery plaque), while HDL (high-density lipoprotein, the so-called good cholesterol carrier) rises (niacin extended-release label) and lipoprotein(a) (an inherited cholesterol-carrying particle) falls (Sahebkar et al., 2016).
  • Flushing: The same receptor on skin immune cells triggers release of prostaglandins (local hormone-like signals that widen blood vessels), producing the flush (Benyó et al., 2005).
  • Vitamin route (all doses): Niacin is converted into NAD+, raising blood NAD+ up to eightfold in a Finnish study (Pirinen et al., 2020).
  • Competing explanations: The rationale that raising HDL protects arteries weakened when trials raised HDL without fewer events. A counter-hypothesis: excess niacin is cleared to 2PY and 4PY (terminal breakdown products), and 4PY inflamed blood vessels in mice (Ferrell et al., 2024).
  • Pharmacology: Niacin acts selectively on HCAR2. Plasma half-life is about one hour (0.9 hours after 2,000 mg extended-release; Menon et al., 2007, Kos-employed authors). The liver clears much of each dose before it reaches the bloodstream by attaching glycine or, via NAD+-derived nicotinamide, methyl groups; the label describes no major cytochrome P450 (liver drug-metabolizing enzyme) pathway. Effects concentrate in fat tissue, liver and skin; breakdown products leave in urine.

Historical Context & Evolution

  • Vitamin origins: Niacin entered medicine through pellagra, a deficiency disease causing skin lesions, diarrhea and dementia; biochemist Conrad Elvehjem discovered niacin in 1937, and it was first used to treat pellagra (Hill, 2021).
  • Lipid drug: In 1955 Rudolf Altschul, Abram Hoffer and James Stephen reported that gram doses lowered serum cholesterol in people (Altschul et al., 1955), making niacin one of the earliest lipid-lowering drugs and the reason it moved from nutrition into cardiology.
  • Early outcome trials: In the Coronary Drug Project (1966–1975), niacin reduced nonfatal repeat heart attacks in men who had already had one, and 15-year follow-up showed fewer deaths (Canner et al., 1986). Angiography (X-ray imaging of coronary arteries) trials combining niacin with other drugs reported slowed artery narrowing (Brown et al., 1990).
  • Statin era: An extended-release prescription form received U.S. approval in 1997 (label). AIM-HIGH (2011) and HPS2-THRIVE (2014), co-funded by the makers of the products tested (Abbott, Merck), added niacin to statins and found no fewer events but more adverse events; the European Medicines Agency suspended the niacin–laropiprant (a flush-blocking drug) products in 2013 (European Medicines Agency).
  • Open questions: Critics note both trials enrolled people with already low LDL, AIM-HIGH’s placebo contained a small dose of immediate-release niacin, and HPS2-THRIVE co-administered laropiprant; neither tested statin-free users or high lipoprotein(a). Since 2020, attention has shifted to niacin as an NAD+ precursor and to its breakdown products.

Expected Benefits

High 🟩 🟩 🟩

Improved Blood Lipid Profile

Gram doses of niacin lower LDL cholesterol, triglycerides and lipoprotein(a) and raise HDL cholesterol by slowing fatty-acid release from fat cells and liver lipoprotein output. This is replicated in placebo-controlled trials from independent groups: AIM-HIGH (Boden), HPS2-THRIVE (Landray), ADMIT (Elam) and a 14-trial lipoprotein(a) meta-analysis (Sahebkar). LDL is a validated surrogate (a lab marker shown to predict events); HDL raising is not, and in statin-treated people these changes did not translate into fewer events. AIM-HIGH was co-funded by Abbott, the Niaspan maker; HPS2-THRIVE by Merck, the laropiprant maker.

Magnitude: Lipoprotein(a) 22.9% lower than placebo (95% CI, confidence interval, the range likely to contain the true value: −27.3% to −18.5%) (Sahebkar et al., 2016); LDL 10 mg/dL lower and HDL 6 mg/dL higher than placebo with niacin–laropiprant (HPS2-THRIVE, Landray et al., 2014); HDL +29% versus 0–2% on placebo (within-group changes; the between-group difference was statistically significant, meaning unlikely to be due to chance, but not given as a figure) (ADMIT, Elam et al., 2000).

Medium 🟩 🟩

No benefit reaches Medium: the only single-trial clinical outcome, erectile function, rests on within-group subgroup changes without a between-group comparison, and the other human data are conflicted, uncontrolled or indirect.

Low 🟩

Fewer Cardiovascular Events ⚠️ Conflicted

Without statins, the Coronary Drug Project cut nonfatal repeat heart attacks, and older trials of niacin alone showed fewer coronary events and strokes (D’Andrea). Statin add-on trials AIM-HIGH and HPS2-THRIVE, and a 23-trial Cochrane review, found no reduction. Net: no benefit on statins; statin-free benefit rests on older trials.

Magnitude: Myocardial infarction (heart attack) risk ratio (RR, risk on niacin divided by risk on control) 0.93 (95% CI 0.87–1.00) across trials (Schandelmaier et al., 2017); AIM-HIGH primary endpoint 16.4% versus 16.2% on placebo, hazard ratio (HR, relative event rate over time) 1.02 (95% CI 0.87–1.21) (Boden et al., 2011); HPS2-THRIVE major vascular events 13.2% versus 13.7% on placebo, rate ratio (event rate on niacin divided by event rate on placebo) 0.96 (95% CI 0.90–1.03) (Landray et al., 2014).

Longer Survival ⚠️ Conflicted

Coronary Drug Project men had lower 15-year mortality, nine years after niacin stopped, an endpoint not pre-specified (Canner). A fatty-liver cohort linked higher dietary niacin to lower mortality, indirectly (Pan et al., 2024). The Cochrane review found no mortality reduction. Net: randomized evidence shows no survival gain.

Magnitude: 15-year mortality 52.0% versus 58.2% on placebo (Canner et al., 1986); all-cause mortality RR 1.05 (95% CI 0.97–1.12) across trials (Schandelmaier et al., 2017).

Slower Atherosclerosis Progression on Imaging ⚠️ Conflicted

Imaging trials showed slowed plaque progression with niacin plus colestipol (FATS, Brown), simvastatin (HATS, Brown) or versus ezetimibe on statins (ARBITER 6, Taylor). The NIA Plaque trial found no added carotid (neck artery) regression over statins (Sibley). Indirect: niacin was always co-administered. Net: imaging benefit is inconsistent.

Magnitude: Average coronary artery narrowing regressed 0.4% on simvastatin–niacin and progressed 3.9% on placebo (within-group changes; the between-group difference was statistically significant but not given as a figure) (Brown et al., 2001); carotid wall volume regressed 0.7% per month on niacin plus statins versus 0.5% per month on statins alone, with no between-group difference (p = 0.49; a p-value, the probability of a difference this large arising by chance alone, here far above the usual 0.05 threshold) (Sibley et al., 2013).

NAD+ Repletion and Muscle Performance in Mitochondrial Myopathy

In an open study of adults with mitochondrial myopathy (inherited muscle energy disease) and matched controls, niacin escalated to 750–1,000 mg/day raised blood and muscle NAD+, increased muscle strength and reduced liver fat (Pirinen). The study was uncontrolled, with no placebo group.

Magnitude: Blood NAD+ rose up to 8-fold, no control group (Pirinen et al., 2020).

Lower Alzheimer’s Risk with Higher Dietary Niacin

In a Chicago cohort aged 65 and older, higher food niacin intake was associated with less Alzheimer’s disease and slower cognitive decline (Morris). Indirect: observational data on dietary amounts, not supplemental doses.

Magnitude: RR 0.3 (95% CI 0.1–0.7) for incident Alzheimer’s disease, highest versus lowest quintile (fifth of the cohort) of total niacin intake from food and supplements; food intake alone was also inversely associated (Morris et al., 2004).

Lower Glaucoma Odds with Higher Dietary Niacin

A meta-analysis of five case-control studies found high dietary niacin intake more common in people without glaucoma (optic nerve disease) than in people with it (Nicola). Indirect: observational data on dietary amounts, not supplemental doses, and the authors note confounding.

Magnitude: Odds ratio (OR, odds of glaucoma with high versus low intake) 0.66 (95% CI 0.55–0.79), glaucoma defined by standard epidemiological criteria (Nicola et al., 2024).

Improved Parkinson’s Motor Symptoms ⚠️ Conflicted

A Veterans Affairs trial of low-dose niacin in 47 people with Parkinson’s disease found no significant motor change in either group at six months, without a between-group comparison; scores improved in both groups during later unblinded niacin treatment (Wakade). Net: no placebo-controlled benefit shown.

Magnitude: UPDRS III (a standard Parkinson’s motor score) change at 6 months −1.06 (95% CI −3.68 to 1.57) on niacin versus −0.05 (95% CI −2.4 to 2.32) on placebo, not compared between groups (Wakade et al., 2021).

Lower Serum Phosphate in Dialysis

In dialysis patients, nicotinic acid and related compounds lowered serum phosphorus, apparently by reducing gut absorption, in a meta-analysis of 12 small studies (Liu). Indirect: pooled data include nicotinamide, and results are compared with baseline.

Magnitude: Serum phosphorus fell by a standardized mean difference (SMD, effect size in standard-deviation units) of 1.05 (95% CI 0.68–1.42) after 8 weeks versus baseline, no control group (Liu et al., 2018).

Correction of Niacin Deficiency (Pellagra)

Niacin reverses pellagra’s dermatitis, diarrhea and dementia; in a case series of 18 adults, mental deterioration responded to niacin and proper diet (Spivak). This matters mainly where intake or absorption is poor.

Magnitude: Not quantified in available studies. The evidence consists of historical case series without comparison groups (Spivak & Jackson, 1977).

Longer Progression-Free Survival in Glioblastoma

In mice with patient-derived glioblastoma (an aggressive brain cancer), niacin reactivated tumor-fighting immune cells and prolonged survival (Sarkar et al., 2020). In an uncontrolled trial adding niacin to standard treatment, immune markers shifted (Poon et al., 2026) and interim progression-free survival (time without tumor growth) exceeded historical controls.

Magnitude: 6-month progression-free survival 82.3% at interim analysis versus 53.9% in historical controls, no control group (Roldan Urgoiti et al., 2025).

Relief of Migraine and Tension-Type Headache

A systematic review of nine articles reported that intravenous or oral niacin may ease migraine and tension-type headaches, with proposed mechanisms of blood-vessel widening and improved cellular energy (Prousky & Seely). No randomized trial has tested this; the evidence is uncontrolled, and some reports used intravenous dosing.

Magnitude: Not quantified in available studies. No randomized trial has measured this outcome, and the included reports are uncontrolled (Prousky & Seely, 2005).

Improved Schizophrenia Symptoms ⚠️ Conflicted

Abram Hoffer’s group reported benefit in its own controlled trials (Hoffer et al., 1957). An independent placebo-controlled trial adding nicotinic acid or nicotinamide to antipsychotics found no difference over six months (Ramsay); a review of controlled trials found no adequate support (Kleijnen & Knipschild). Net: independent trials show no benefit.

Magnitude: No statistically significant difference from placebo when added to antipsychotic drugs for six months; the abstract reports no outcome figure (Ramsay et al., 1970).

Improved Erectile Function in Men with Dyslipidemia

In a single-center placebo-controlled trial of 160 men with erectile dysfunction and dyslipidemia (abnormal blood fats), up to 1,500 mg/day niacin for 12 weeks improved International Index of Erectile Function scores from baseline in moderate or severe dysfunction (Ng). Placebo scores also rose, and no between-group comparison was reported.

Magnitude: Erectile-function domain score rose 5.28 points on niacin versus 2.65 on placebo in severe dysfunction, and 3.31 versus 2.74 in moderate dysfunction (within-group changes, not compared between groups) (Ng et al., 2011).

Speculative 🟨

Lower Inflammatory Markers

A meta-analysis of 15 trials found niacin lowered C-reactive protein (a blood inflammation marker) and tumor necrosis factor-alpha (an inflammatory signaling protein) (Rad et al., 2024). These are unvalidated biomarkers, not clinical outcomes.

Improved Endothelial Function ⚠️ Conflicted

A seven-trial meta-analysis found niacin improved flow-mediated dilation, an ultrasound measure of artery-lining function (Sahebkar, 2014); a randomized trial on statins found no improvement (Philpott et al., 2013). Net: an unvalidated biomarker with inconsistent results.

Benefit-Modifying Factors

  • Genetic polymorphisms: The variant rs10496731 raises blood 2PY and 4PY and soluble VCAM-1 (vascular cell adhesion molecule-1, a vessel-inflammation marker) (Ferrell et al., 2024); whether carriers gain less net vascular benefit is untested.
  • Baseline triglycerides: In the Stockholm trial, the mortality benefit of clofibrate plus nicotinic acid appeared only with triglycerides above 1.5 mmol/L (Carlson & Rosenhamer, 1988).
  • Baseline LDL and lipoprotein(a): AIM-HIGH enrolled people with median LDL of 74 mg/dL, leaving little to correct (Boden et al., 2011); elevated lipoprotein(a) gives niacin a target few other oral agents reduce.
  • Baseline NAD+ status: People with mitochondrial myopathy had systemic NAD+ deficiency, and niacin brought their muscle NAD+ up to control levels (Pirinen et al., 2020); benefit in adults with normal NAD+ is unknown.
  • Sex: In pooled extended-release trials, women had larger LDL reductions than men at the same dose (Goldberg, 2004); the label notes women may respond at lower doses.
  • Pre-existing conditions: Event reductions appeared in trials without statins, suggesting more relevance for statin-intolerant people (D’Andrea et al., 2019); in diabetes, rising glucose may offset benefit.
  • Age: The label reports no overall efficacy differences in participants aged 65 and older (21% of trial participants); the Coronary Drug Project enrolled only men aged 30–64 (Canner et al., 1986).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Flushing and Vasodilatory Symptoms

Warmth, redness, itching and tingling of the face and upper body after dosing, driven by receptor-triggered prostaglandin release; dizziness, palpitations and, rarely, fainting can accompany it, and tolerance develops over weeks. Documented by independent groups: the label’s placebo-controlled trials (Kos/AbbVie), McKenney’s formulation trial, AIM-HIGH (Boden) and HPS2-THRIVE (Landray), where about one-third of participants in the pre-randomization trial phase were excluded, mainly for niacin side effects (HPS2-THRIVE, 2013). Flushing is the leading reason people stop.

Magnitude: Discontinuation for flushing 6% versus 0% on placebo; flushing in 55–69% at maintenance doses of extended-release niacin versus 19% on placebo (label); discontinuation for any side effect RR 2.17 (95% CI 1.70–2.77) across 17 trials (Schandelmaier et al., 2017).

New-Onset Diabetes and Worsened Glucose Control

Niacin raises fasting glucose; a proposed mechanism is rebound fatty-acid release that reduces insulin sensitivity. A meta-analysis of 11 trials (Goldie) found more new diabetes regardless of statin or laropiprant use; HPS2-THRIVE (Landray) found excess serious diabetes disturbances; Garg and Grundy reported HbA1c (a 3-month average blood-sugar measure) rising 21% in type 2 diabetes. ADMIT (Elam) found only modest glucose rises and unchanged HbA1c, so size varies with dose and population.

Magnitude: New-onset diabetes RR 1.34 (95% CI 1.21–1.49): 725 of 13,121 on niacin versus 646 of 13,219 on control, one extra case per 43 people treated for 5 years (number needed to harm, NNH, as reported) (Goldie et al., 2016).

Gastrointestinal Adverse Events

Nausea, diarrhea, vomiting, indigestion and, rarely, peptic ulcer activation. Documented in the label’s placebo-controlled trials, as serious events in AIM-HIGH (Anderson) and HPS2-THRIVE (Landray), and as the leading withdrawal cause with sustained-release niacin (McKenney). Taking doses with food reduces symptoms.

Magnitude: Serious gastrointestinal adverse events 7.4% versus 5.5% on placebo (Anderson et al., 2014); absolute excess of 1.0 percentage point over placebo in HPS2-THRIVE, group rates not given in the abstract (Landray et al., 2014).

Medium 🟥 🟥

Liver Toxicity

Ranges from transaminase (liver enzyme) rises to sudden, severe liver failure, concentrated in sustained-release products (slow release over 12 hours or more) and when these replace immediate-release niacin at equal doses. In McKenney’s randomized comparison, half of sustained-release users developed hepatotoxicity versus none on immediate-release. HPS2-THRIVE showed a small excess of persistent ALT (alanine aminotransferase, a liver enzyme) elevations.

Magnitude: Hepatotoxicity in 12 of 23 (52%) on sustained-release versus 0 of 23 on immediate-release (McKenney et al., 1994); consecutive ALT above 3 times the upper limit of normal 0.10%/year versus 0.06%/year on placebo (HPS2-THRIVE Collaborative Group, 2013).

Serious Infections

An unexpected excess of serious infections appeared in HPS2-THRIVE (Landray, niacin with laropiprant) and on re-analysis of AIM-HIGH (Anderson, niacin alone), whose authors called the finding provisional and exploratory. The mechanism is unknown.

Magnitude: Serious infections 8.1% versus 5.8% on placebo (Anderson et al., 2014); absolute excess of 1.4 percentage points over placebo, group rates not given in the abstract (Landray et al., 2014).

Hyperuricemia and Gout

Niacin raises blood uric acid (hyperuricemia), which can precipitate gout attacks. A randomized crossover trial in type 2 diabetes found consistent uric acid increases (Garg and Grundy), and the label lists gout among post-marketing reports and advises caution in gout-prone people. In the HATS safety analysis, indirect because simvastatin was co-administered, new uric acid elevations were not significantly more frequent than on placebo (Zhao).

Magnitude: New-onset uric acid ≥7.5 mg/dL in 18% on simvastatin–niacin versus 15% on placebo, not significant (Zhao et al., 2004); uric acid rose consistently on 4.5 g/day compared with untreated control periods, with no figure in the abstract (Garg & Grundy, 1990).

Skin Rash and Acanthosis Nigricans

Rashes, dry skin and acanthosis nigricans (dark, velvety skin thickening in body folds) occur apart from flushing. In the label’s placebo-controlled trials, rash led to discontinuation more often than placebo, and acanthosis nigricans was a leading withdrawal cause on immediate-release niacin (McKenney). HPS2-THRIVE (Landray) found excess serious skin events, indirect because laropiprant was co-administered. Most niacin adverse effects resolve with dose reduction or stopping (Young & Gazzard, 2025).

Magnitude: Discontinuation for rash 2% versus 0% on placebo (label); serious skin adverse events absolute excess of 0.3 percentage points over placebo, group rates not given in the abstract (Landray et al., 2014).

Low 🟥

Myopathy with Statins

HPS2-THRIVE (niacin–laropiprant plus simvastatin) quadrupled definite myopathy (muscle damage), mostly in Chinese participants. Indirect: tested only with laropiprant; the label also warns of rhabdomyolysis (severe muscle breakdown) with niacin of 1 g/day or more plus statins.

Magnitude: Definite myopathy 0.16%/year versus 0.04%/year on placebo, RR 4.4 (95% CI 2.6–7.5) (HPS2-THRIVE Collaborative Group, 2013).

Bleeding ⚠️ Conflicted

HPS2-THRIVE found excess serious bleeding with niacin–laropiprant; AIM-HIGH, testing niacin alone, found no significant difference (Anderson). The label reports small platelet reductions and prolonged prothrombin time (a clotting-time test). Net: niacin alone showed only a non-significant numerical excess of serious bleeding.

Magnitude: Serious bleeding 3.4% versus 2.9% on placebo, not significant (Anderson et al., 2014); absolute excess of 0.7 percentage points over placebo in HPS2-THRIVE, group rates not given in the abstract (Landray et al., 2014).

Ischemic Stroke ⚠️ Conflicted

AIM-HIGH recorded more ischemic strokes (strokes caused by a blocked artery) on niacin, at the borderline of statistical significance (P = 0.050), but not after adjusting for known risk factors (Teo). The Cochrane review found no stroke increase across trials. Net: no consistent stroke risk.

Magnitude: Ischemic stroke 1.86% versus 1.06% on placebo, HR 1.78 (95% CI 1.00–3.17) (Teo et al., 2013); fatal or nonfatal stroke RR 0.95 (95% CI 0.74–1.22) across trials (Schandelmaier et al., 2017).

Cystoid Macular Edema

Fluid accumulation in the central retina causing blurred vision, reported mostly with gram doses, occasionally lower, and usually reversible after stopping. The evidence is case series and reports (Gass, 1973; a literature review), and the label lists macular edema post-marketing.

Magnitude: Not quantified in available studies. Only case reports and case series exist, without comparison groups.

Vascular Inflammation from Niacin Breakdown Products

Higher blood 4PY and 2PY, terminal products of excess niacin, were associated with more major cardiovascular events in U.S. and European cohorts, and 4PY induced vessel inflammation in mice (Ferrell). Indirect: measures the body’s own metabolite levels, not supplementation.

Magnitude: 4PY adjusted HR 1.89 (95% CI 1.26–2.84) in the U.S. cohort and 1.99 (95% CI 1.26–3.14) in the European cohort for 3-year major adverse cardiovascular events; a 2024 publisher correction changed only a figure label (Ferrell et al., 2024).

Speculative 🟨

Increased Methyl-Group Demand and Homocysteine

Clearing excess niacin consumes methyl groups; homocysteine (a vascular-risk amino acid) rose 55% versus a 7% fall on placebo in an ADMIT substudy (Garg et al., 1999). Homocysteine is an unvalidated biomarker.

Risk-Modifying Factors

  • Genetic polymorphisms: No genetic test predicting response is validated; the rs10496731 variant raises 2PY and 4PY (Ferrell et al., 2024), potentially modifying vascular-inflammation risk, untested.
  • Ancestry: Chinese HPS2-THRIVE participants had any-myopathy rates of 0.66%/year on niacin–laropiprant versus 0.07%/year in Europeans (HPS2-THRIVE, 2013).
  • Baseline glucose and liver enzymes: People with diabetes or prediabetes may see dose-related glucose intolerance, and active liver disease or unexplained transaminase elevations are contraindications (label).
  • Sex: Women reach higher steady-state blood levels of niacin and its metabolites than men at equal doses, and adverse events were more frequent in women than men in the label’s placebo-controlled trials (label).
  • Pre-existing conditions: Gout, peptic ulcer, kidney impairment, alcohol use, uncontrolled hypothyroidism and diabetes increase risk of specific adverse effects (label).
  • Age: Older age raises rhabdomyolysis risk with statins (label), and age above 65 independently predicted ischemic stroke in AIM-HIGH (Teo et al., 2013).

Key Interactions & Contraindications

  • Statins (atorvastatin, simvastatin, rosuvastatin): Caution; niacin ≥1 g/day raises myopathy and rhabdomyolysis risk (label). Label studies found no fluvastatin and small lovastatin and simvastatin changes; another found about 60% higher simvastatin acid exposure, deemed minor (Lauring et al., 2015, Merck authors). Muscle symptoms are monitored.
  • Other lipid-lowering drugs (ezetimibe, fenofibrate): Monitor; ezetimibe–simvastatin co-administration raised drug exposures up to 35%, judged not clinically significant (Kosoglou et al., 2011, Merck authors); a fenofibrate peak-level interaction could not be ruled out (Penn et al., 2006). Kosoglou’s authors recommend monitoring during titration.
  • Bile acid sequestrants (resins binding bile acids in the gut: cholestyramine, colestipol): Caution; they bind niacin and reduce absorption (label). The label separates doses by 4–6 hours.
  • Blood pressure-lowering and blood-vessel-active drugs (nitrates such as nitroglycerin, calcium channel blockers such as amlodipine, alpha-blockers such as doxazosin): Caution; additive postural hypotension (blood pressure drop on standing) (label). Rising slowly and staggering dose changes limit this.
  • Glucose-lowering drugs (metformin, insulin, sulfonylureas): Monitor; niacin raises glucose and may require diabetes-medication adjustment (label). Glucose is checked during the first months.
  • Anticoagulants and antiplatelets (blood thinners: warfarin, apixaban, clopidogrel): Monitor; bleeding risk: niacin lowers platelets about 11% and prolongs prothrombin time about 4% (label); a case report linked a niacin dose increase to critically elevated INR (a clotting-time test) on warfarin (Christopher, 2011). INR is monitored.
  • Aspirin (over-the-counter): Beneficial interaction; 325 mg 30 minutes before niacin reduced flushing in a randomized trial (Thakkar et al., 2009, Abbott authors), and aspirin raised blood niacin levels, which the authors attribute to reduced clearance (Ding et al., 1989), with unclear relevance.
  • Alcohol: Caution; intensifies flushing and adds liver risk (label). The label advises against alcohol around dosing.
  • Other niacin or nicotinamide sources (B-complex, multivitamins, nicotinamide riboside): Caution; additive niacin-related adverse effects (label). Total daily intake from all sources is the relevant dose.
  • Red yeast rice (monacolin K, chemically identical to lovastatin): Caution (theoretical); additive myopathy and liver risk by analogy with statins. Muscle symptoms and liver enzymes are the monitoring focus.
  • Hepatotoxic supplements (green tea extract, kava): Caution (theoretical); additive liver injury risk, greatest with gram-dose niacin. Liver enzymes are the monitoring focus.
  • Supplements with additive lipid effects (fish oil, berberine, plant sterols): Monitor (theoretical); additive triglyceride or LDL lowering, generally desired, and berberine may offset niacin’s glucose rise. Lipid tracking separates the effects.
  • Laboratory tests: Monitor; niacin can falsely elevate some catecholamine (stress hormones such as adrenaline) assays and cause false-positive urine glucose with Benedict’s reagent (label). Laboratories can account for niacin use when informed.
  • Hot drinks, spicy food and heat exposure: Caution; hot beverages and spicy foods increase flushing (label); sauna heat may do so (theoretical). Spacing them from dosing reduces flushing.

Populations who should avoid Niacin:

  • Active liver disease, or unexplained transaminase elevations; stop if levels persist at or above 3 times the upper limit of normal (label)
  • Active peptic ulcer disease (label)
  • Arterial bleeding (label)
  • Known hypersensitivity to niacin product components (label)
  • Pregnancy, when used for high cholesterol (label)
  • Breastfeeding during treatment with drug doses (label)
  • Unstable angina (worsening chest pain at rest) or acute heart attack, particularly with blood-vessel-active drugs: use only with caution (label)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Immediate-release or extended-release forms only: Excluding sustained-release products avoids the hepatotoxicity seen in half of sustained-release users (McKenney et al., 1994); forms are not switched at equal doses.
  • Slow titration: Extended-release protocols start at 500 mg at bedtime and rise by no more than 500 mg per 4 weeks (label), reducing flushing and gastrointestinal upset.
  • Aspirin pretreatment: Aspirin 325 mg about 30 minutes before dosing reduces flushing and flushing-related discontinuation (Thakkar et al., 2009), at the cost of aspirin’s own bleeding risk.
  • Low-fat snack, no triggers: Dosing with food and avoiding alcohol, hot drinks and spicy foods around dosing reduces flushing and stomach upset (label).
  • Liver enzyme stopping rule: Transaminases are checked before starting, every 6–12 weeks in year one, then about every 6 months; use stops if they persist at 3 times the upper limit of normal or with symptoms (label), limiting liver injury.
  • Glucose surveillance: Fasting glucose and HbA1c at baseline and at 3 months detect the new-onset diabetes risk early.
  • Statin co-use precautions: Prompt reporting of muscle pain, weakness or dark urine, with creatine kinase (a muscle-damage enzyme) testing if symptoms appear, limits myopathy progression.
  • Gout precautions: Baseline uric acid testing, and avoiding gram doses after prior gout, limits gout flares.
  • Dose ceilings: Extended-release doses above 2,000 mg/day are not recommended (label); staying below them limits dose-dependent flushing, liver and glucose effects.

Therapeutic Protocol

Timing, titration steps, splitting and cycling below reflect common practice unless cited.

  • Nutritional dose: Recommended intake is 16 mg/day for men and 14 mg/day for women (Institute of Medicine, 1998); supplemental upper limits are 35 mg/day (U.S.) and 10 mg/day (Europe), set by flushing (Minto et al., 2017).
  • Lipid-modifying dose (extended-release): 500 mg at bedtime for 4 weeks, then 1,000–2,000 mg once nightly (label); AIM-HIGH used 1,500–2,000 mg/day (Boden et al., 2011).
  • Lipid-modifying dose (immediate-release): Trials reached 3,000 mg/day (Elam et al., 2000); cardiologist William Davis (Track Your Plaque) starts at 250 mg, targeting 750–1,000 mg/day for HDL and 1,000 up to 4,000–5,000 mg/day for LDL or lipoprotein(a) (Davis, 2007).
  • NAD+-oriented dose: Slow-release niacin escalated by 250 mg/month to 750–1,000 mg/day, the Helsinki regimen of Anu Suomalainen’s group (Pirinen et al., 2020).
  • Orthomolecular (megavitamin) approach: Abram Hoffer, co-author of the first gram-dose cholesterol report (Altschul et al., 1955), and Andrew Saul promote multi-gram immediate-release niacin for broad indications; these doses lack outcome trials beyond the lipid studies above.
  • Time of day: Extended-release at bedtime after a low-fat snack (label); immediate-release with meals.
  • Half-life: Plasma half-life is about one hour (Menon et al., 2007); lipid effects persist because metabolic changes outlast blood levels.
  • Single versus split dosing: Extended-release is taken once daily; immediate-release is split into two or three doses with meals, though Davis advises no more than two (Davis, 2007).
  • Genetic polymorphisms: No variant guides dosing; Chinese participants had higher myopathy rates with statins (HPS2-THRIVE, 2013), a factor weighed when choosing doses alongside statins.
  • Sex: Women may respond at lower doses (label), so titration can stop earlier once targets are met.
  • Age: Older adults on statins carry higher rhabdomyolysis risk (label); slower titration and muscle-symptom vigilance apply.
  • Baseline biomarkers: Elevated lipoprotein(a), triglycerides or low NAD+ define the target; low LDL already on statins predicts little added benefit (Boden et al., 2011).
  • Pre-existing conditions: Diabetes, prediabetes, gout, liver disease or peptic ulcer history favor lower doses, closer monitoring or avoidance (label).

Discontinuation & Cycling

  • Duration: Lipid-modifying use is long-term, since effects fade after stopping; nutritional intake is lifelong; NAD+-oriented use has been studied only up to 10 months (Pirinen et al., 2020).
  • Withdrawal effects: No withdrawal syndrome is described; blood fats return toward baseline over weeks after stopping.
  • Restarting: After an extended break, the label calls for restarting with a titration phase (label).
  • Tapering: Not required for safety; the Helsinki NAD+ study tapered by 250 mg/month at study end (Pirinen et al., 2020).
  • Cycling: Not part of studied protocols; skipping days resets flushing tolerance and no evidence shows cycling preserves efficacy.

Sourcing and Quality

  • Know the form: Immediate-release (crystalline) niacin is sold as a supplement; extended-release niacin (Niaspan and generics) is prescription-only in the U.S. (label); sustained-release supplements carry the highest liver risk (McKenney et al., 1994).
  • “No-flush” products: These usually contain inositol hexanicotinate (a niacin-inositol compound) or nicotinamide, which lack niacin’s cholesterol effect (Examine); the label notes nicotinamide has no lipid-lowering activity.
  • Over-the-counter modified-release brands: Wax-matrix Endur-acin improved blood fats in short trials, with limited safety data (Dunatchik et al., 2012); Slo-Niacin is another over-the-counter controlled-release product.
  • Third-party testing: USP (United States Pharmacopeia) Verified or NSF (NSF International) certification, or approval in ConsumerLab testing (ConsumerLab), indicates verified contents; ConsumerLab found label-accuracy failures among B vitamin products.
  • Dose accuracy: Single-ingredient products in 100–500 mg units allow slow titration, and avoiding high-dose B-complex formulas prevents unintended stacking.

Practical Considerations

  • Time to effect: Full lipid effects may take three months or longer (Davis, 2007); the Helsinki study measured NAD+ and muscle changes after 4 months in controls and 10 months in patients (Pirinen et al., 2020).
  • Common pitfalls: Substituting sustained-release for immediate-release at equal doses, buying “no-flush” products expecting lipid effects, rapid dose escalation, and dosing on an empty stomach (label).
  • Regulatory status: In the U.S., extended-release niacin is an FDA (Food and Drug Administration)-approved prescription drug whose label states it did not reduce cardiovascular events on simvastatin (label); the EU suspended niacin–laropiprant in 2013 (European Medicines Agency).
  • Cost and payer incentives: Niacin is an inexpensive generic; insurers and health systems have a financial incentive to favor it over costly injectable lipid drugs, so any payer-driven bias in guidelines would run in niacin’s favor.
  • Flush versus heart attack: Flushing can mimic cardiac symptoms; the label advises learning how they differ (label).

Interaction with Foundational Habits

  • Sleep: Indirect; bedtime extended-release dosing (label) can cause night-time flushing that disrupts sleep, and insomnia appears in post-marketing reports. Aspirin pretreatment and slow titration limit awakenings; immediate-release dinner dosing is an alternative.
  • Nutrition: Direct; alcohol, hot drinks and spicy foods worsen flushing, and dosing with a low-fat snack reduces upset (label). Dietary tryptophan (an amino acid the body partly converts into niacin) adds to intake. Niacin’s glucose rise argues for attention to carbohydrate quality.
  • Exercise: Blunting; niacin during prolonged cycling prevented the normal rise in blood fatty acids and raised growth hormone; the authors inferred reduced high-intensity capacity, though performance times did not differ significantly (Murray et al., 1995). Dosing away from long or intense sessions avoids reduced fat fuel.
  • Stress management: Indirect, uncertain relevance; intravenous nicotinic acid raised plasma cortisol in healthy men, apparently independent of its fat-release effect (Quabbe et al., 1983), but oral supplemental doses are untested. Flush episodes can feel alarming, so anticipating them and recognizing tolerance development reduces distress.

Monitoring Protocol & Defining Success

Before starting gram doses, baseline testing establishes liver, glucose, uric acid and lipid status, because niacin’s main harms are liver injury, rising glucose and gout, and its main expected change is in blood fats; NAD+ testing is optional and research-grade. Baseline platelets and creatine kinase add value for people on anticoagulants or statins.

Ongoing monitoring follows the label cadence for liver enzymes: at 6–12 weeks, then every 6–12 weeks through the first year, then about every 6 months (label). Glucose, HbA1c, uric acid and lipids are rechecked at 3 months and after each dose increase, then every 6–12 months. Success means the targeted lipid change from one’s own baseline without new diabetes, liver enzyme rises or gout.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT and AST (liver enzymes) Roughly 7–55 U/L for ALT and 8–48 U/L for AST (standard reference range) Safety check: stop if persistently ≥3× upper limit AST is aspartate aminotransferase; ranges vary by laboratory; stop rule per the label; avoid heavy exercise 48 hours before
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: rising values may change use Fasting 8–12 hours; pair with HbA1c
HbA1c 4.0–5.6% (standard reference range) Safety check for new-onset diabetes Reflects about 3 months; no fasting needed
Uric acid About 3.4–7.0 mg/dL in men and 2.4–6.0 mg/dL in women (standard reference range) Safety check for gout risk Ranges vary by laboratory; pair with symptom history
LDL, HDL, triglycerides No established target; track change from own baseline Expected to change with niacin Fasting improves triglyceride accuracy; LDL validated surrogate, HDL not
Apolipoprotein B No established target; track change from own baseline Expected to change with niacin Apolipoprotein B counts plaque-forming particles; no fasting needed
Lipoprotein(a) No established target; track change from own baseline Expected to change with niacin Largely genetic; measure once at baseline, again at 3 months
Creatine kinase About 30–200 U/L (standard reference range) Safety check with statins Measure if muscle symptoms occur; exercise raises values
Platelets and prothrombin time Platelets 150–450 ×10⁹/L; prothrombin time about 11–13.5 seconds (standard reference range) Safety check with anticoagulants Niacin lowers platelets about 11% at 2,000 mg (label)
Blood NAD+ No established target; track change from own baseline Expected to change with niacin Research-grade assays; rose up to eightfold in the Helsinki study (Pirinen et al., 2020)

Qualitative markers to track:

  • Flushing frequency and severity, and whether tolerance develops
  • Gastrointestinal comfort
  • Sleep continuity on bedtime dosing
  • Muscle aches or weakness, especially with statins
  • Vision changes such as central blurring
  • Joint pain suggestive of gout
  • Energy and exercise tolerance

Emerging Research

  • Glioblastoma adjunct (NCT04677049): Phase 1–2 study of controlled-release niacin with radiotherapy and temozolomide (a chemotherapy drug) in 59 patients, active, not recruiting, completion December 2027; interim survival (Roldan Urgoiti et al., 2025) and immune results (Poon et al., 2026) published. Positive: final data would firm up the Low benefit; null: the interim signal fades.
  • Prediabetes remission (CONCEPT, NCT07286747): Phase 2, 390 participants, nicotinic acid released in the lower small intestine, 100–200 mg/day versus placebo, completion December 2028. Positive: a gut-targeted low dose could reverse niacin’s glucose signal; null: glucose concerns remain unopposed.
  • Alzheimer’s disease (NCT06582706): Phase 1–2, 30 participants, nicotinic acid 500 mg versus placebo, measuring blood and spinal-fluid levels, recruiting, completion December 2026. Positive: brain exposure would justify efficacy trials; null: brain benefits remain observational only.
  • Fatty liver (NCT06843148): 36 participants, low-dose post-meal niacin 750 mg versus placebo for liver fat flux, completion July 2030. Positive: supports the Helsinki liver-fat finding (Pirinen et al., 2020); null: that finding remains uncontrolled.
  • Glaucoma (optic nerve disease) NAD+ precursors (NCT06991712): Phase 2, 138 participants comparing nicotinic acid 350 mg with nicotinamide, nicotinamide riboside and NMN (nicotinamide mononucleotide) versus placebo on visual fields; primary completion (December 2025) passed, still listed recruiting, no results posted. Positive: niacin gains a nerve-protection signal; null: eye benefits stay limited to nicotinamide research.
  • Completed Parkinson’s trial (NCT03462680): Completed April 2020 with results posted and published, showing no placebo-controlled motor benefit (Wakade et al., 2021); larger trials would be needed to change this.
  • Breakdown-product risk: Whether supplemental niacin raises 4PY enough to increase cardiovascular risk is untested (Ferrell et al., 2024); trials measuring 4PY could weaken or clear the safety case.
  • Lipoprotein(a)-specific therapies: Lp(a)HORIZON (NCT04023552), 8,323 participants randomized to injected pelacarsen or placebo, completed July 2026; topline results lowered lipoprotein(a) but missed the primary cardiovascular endpoint (Novartis, 2026), weakening the rationale for niacin’s 23% reduction (Sahebkar et al., 2016).

Conclusion

Niacin is both an essential vitamin and, at doses far above dietary needs, a long-established drug for changing blood fats. At those doses it reliably lowers harmful cholesterol, other blood fats and an inherited cholesterol-carrying particle linked to heart disease, while raising so-called good cholesterol. Whether these changes translate into fewer heart attacks or longer life is where the evidence divides. Older trials in people not taking statins pointed toward fewer repeat heart attacks and possibly longer survival, while the large modern trials that added niacin to statins found no reduction in heart events and more side effects. Those modern trials were funded partly by the manufacturers of the niacin products tested, and their designs leave untested people who cannot take statins or who carry high levels of that inherited particle.

The side-effect profile is well documented: flushing, digestive upset, higher blood sugar and a higher chance of developing diabetes, along with possible liver injury, gout and, less certainly, infections. Liver risk depends strongly on the product form.

Interest in niacin for healthy aging now centers on its role in cellular energy and on whether its breakdown products harm blood vessels, but this rests on small uncontrolled studies, links seen in population studies and animal work. For health-focused adults, the evidence for niacin is strongest where other cholesterol treatments are unsuitable and weakest for niacin as a general longevity supplement.

Top - Benefits - Risks - Protocol